CONFIDENTIAL TREATMENT REQUEST
[*] INDICATES INFORMATION THAT HAS
BEEN OMITTED PURSUANT TO A
CONFIDENTIAL TREATMENT REQUEST AND
THIS INFORMATION HAS BEEN FILED UNDER
SEPARATE COVER WITH THE COMMISSION
BIONUTRICS, INC.
2415 EAST CAMELBACK ROAD, SUITE 700
PHOENIX, ARIZONA 85022
September 27, 2005
Nirmal Mulye, Ph.D.
President
Nostrum Pharmaceuticals, Inc.
505 Thornall Street, Suite 304
Edison, NJ 08837
Nirmal Mulye, Ph.D.
Director
Emem Nostrum Remedies, Pvt. Ltd.
Camlin House
Andheri (E), Mumbai 400 059
India
Re: Assumption of Enem Nostrum Remedies Pvt. Ltd. Obligations
Dear Nirmal:
This letter serves to confirm the
agreements between and among Bionutrics, Inc.
("Bionutrics"), Nostrum Pharmaceuticals,
Inc. ("Nostrum") and Enem Nostrum
Remedies Pvt. Ltd. ("Enem") regarding the
above-reference matters, as follows:
(a) Effective September 14, 2005, Bionutrics will assume, and Enem
will
discharge, Nostrum's obligation to pay Enem
$1,191,113.00 for its work in the
development of pharmaceutical products for
which it has previously submitted
invoices, a list of which you have given to
Bionutrics.
(b) Effective September 27, 2005, Bionutrics will assume, and Enem
will
discharge, Nostrum's additional obligation
to pay Enem $316,979.00 for its work
in the development of pharmaceutical
products for which it has previously
submitted invoices, a list of which you
have given to Bionutrics.
In
